In a 36-year-old woman with classic attention‑deficit/hyperactivity disorder symptoms, should initial treatment be started with methylphenidate (Ritalin) or mixed amphetamine salts (Adderall)?

Either Methylphenidate (Ritalin) or Mixed Amphetamine Salts (Adderall) Can Be Started as First-Line Treatment

Both methylphenidate and mixed amphetamine salts are appropriate first-line pharmacological treatments for ADHD in adults, with the choice based on individual patient factors rather than superior efficacy of one over the other. 1

Evidence Supporting Either Agent as First-Line

The 2002 American Academy of Child and Adolescent Psychiatry practice parameter explicitly states that treatment "should be started with low doses of either MPH, DEX, or AMP" 1. This guideline applies to adults as well, noting that "adults or older adolescents may be started on doses of 5 mg of MPH, DEX, or AMP" 1.

Comparative Efficacy

While a meta-analysis suggests Adderall has a "small but statistically significant advantage" over standard-release methylphenidate 2, this finding has limited clinical relevance for several reasons:

• The advantage was "strongest for global ratings" but not consistently significant across all measures 2
• The comparison was against immediate-release methylphenidate, not modern extended-release formulations
• A more recent 2019 meta-analysis in adults found methylphenidate had a moderate effect size (SMD -0.50) while mixed amphetamine salts also showed moderate effects (SMD -0.64) 3

Approximately 70% of patients respond to either methylphenidate or amphetamines alone, and nearly 90% respond if both are tried sequentially 1. This suggests the agents have comparable overall efficacy with individual variation in response.

Practical Considerations for Selection

Start with Methylphenidate If:

• Lower abuse potential is a concern: Methylphenidate has "pharmacokinetic properties that reduce its abuse potential compared with stimulant drugs of abuse" 4
• Shorter duration needed initially: Immediate-release methylphenidate has a 2-hour half-life with 4-6 hours of clinical action 4
• Less impact on appetite/sleep desired: "Problematic effects on appetite and sleep are greater with AMP or DEX, consistent with their longer excretion half-lives" 1

Start with Mixed Amphetamine Salts If:

• Longer duration of action needed: Amphetamines have longer half-lives (10.4 hours for d-amphetamine, 12.3 hours for l-amphetamine) 5
• Once-daily dosing preferred: Amphetamines "may require only once-a-day dosing" 1
• Patient previously responded to amphetamine-based medications

Dosing Algorithm

Methylphenidate Starting Regimen:

• Start: 5 mg twice daily (after breakfast and lunch) 1
• Titrate: Increase by 5-10 mg weekly based on response 1
• Target range: 20-65 mg total daily dose for adults 1
• Maximum: Up to 1.0 mg/kg or 65 mg daily 1

Mixed Amphetamine Salts Starting Regimen:

• Start: 5-10 mg once daily in the morning 6, 1
• Titrate: Increase by 5 mg weekly 6
• Target range: 20-40 mg total daily dose 1
• Maximum: Up to 0.9 mg/kg or 40 mg daily (some patients may require up to 50 mg) 6, 1

Monitoring and Switching Strategy

Baseline assessment required 1:

• Blood pressure and pulse
• Height and weight
• Cardiovascular history screening
• Substance abuse history

If first agent fails or causes intolerable side effects, switch to the alternative stimulant 1. This sequential trial approach captures the 90% of patients who respond to at least one stimulant 1.

Key Contraindications (Both Agents)

• Uncontrolled hypertension, coronary artery disease, or tachyarrhythmias 4, 1
• Active psychotic disorder 1
• MAO inhibitor use within 14 days 1, 7
• Known hypersensitivity to the specific medication 8, 7

Common Pitfalls

Avoid premature discontinuation: Many patients require dose titration over several weeks to achieve optimal response. The mean effective dose for amphetamines in one adult study was only 10.77 mg/day 9, suggesting lower doses may be effective.

Monitor for anxiety exacerbation: In patients with comorbid anxiety, amphetamines may precipitate acute anxiety symptoms 9. Consider methylphenidate first in this population.

Don't assume tolerance indicates treatment failure: Document that symptoms cannot be controlled at lower doses before escalating to higher doses, and monitor for signs of true tolerance versus inadequate initial dosing 1.